MARKET

SCNLF

SCNLF

Scancell Holdings Plc London
OTCPK
0.124
NaN%
Opening 09:30 08/20 EDT
OPEN
--
PREV CLOSE
0.124
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.313
52 WEEK LOW
0.124
MARKET CAP
149.71M
P/E (TTM)
-17.6429
1D
5D
1M
3M
1Y
5Y
1D
Scancell Wins UK Green Light for Global Phase 3 Melanoma Trial of iSCIB1+
TipRanks · 1d ago
Scancell Extends CSO Share Option Exercise Period
TipRanks · 07/31 06:08
Scancell Raises £15.7m After Oversubscribed Retail Offer and UK Placing
TipRanks · 07/27 06:08
Scancell and Neuphoria in all-share merger backed by $89m financing for melanoma trial
TipRanks · 07/24 06:32
Scancell upsizes oversubscribed £13m UK placing to extend funding runway
TipRanks · 07/23 15:32
Scancell launches discounted UK share placing to fund Phase 3 melanoma trial
TipRanks · 07/23 07:08
Scancell launches retail offer and placing to extend cash runway into 2027
TipRanks · 07/23 07:07
Scancell to Merge with Neuphoria and Secure Up to $89m for Phase 3 Melanoma Trial
TipRanks · 07/23 07:07
More
About SCNLF
Scancell Holdings plc is a clinical-stage biopharmaceutical company. The Company is engaged in studying the human adaptive immune system, to generate medicines to treat unmet needs in cancer. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its product pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2, SC129, SC134, SC2811, SC27, and others. Modi-1 is the first therapeutic vaccine candidate from the Company’s Moditope platform, which targets citrullinated peptides from two different proteins which have been combined to reduce the possibility of tumor escape and have each been conjugated to a toll-like receptor (TLR) 1/2 agonist, which acts as an adjuvant. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company’s Moditope platform and has the potential to address different cancer indications to Modi-1.

Webull offers Scancell Holdings Plc stock information, including OTCPK: SCNLF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SCNLF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SCNLF stock methods without spending real money on the virtual paper trading platform.